Everest Medicines

Veja o organograma con seus 15 executivos principais

Biografias mais buscadas da Everest Medicines

• Yongqing Luo, Executive Director and Chief Executive Officer
• Wei Fu, Chairman of the Board
• Shidong Jiang, Independent Non-Executive Directors

Recentes movimentos de executivos em Everest Medicines

• Sandra Zeng, ingressou na Companhia como Chief Medical Officer  (Notícia publicada em 18 de março de 2024).
• Rico Liang, ingressou na Companhia como Chief Product Officer  (Notícia publicada em 18 de março de 2024).
• Lan Kang, Director, deixou a Companhia  (Notícia publicada em 14 de janeiro de 2024).

Clique aqui para ver outras movimentos em Everest Medicines

Criar um alerta
para seguir os movimentos de executivos da Everest Medicines.

Everest Medicines possui 1.867 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Johnson & Johnson (Estados Unidos).

Popular M&A news in Farmacêutica

• AstraZeneca has announced the acquisition of Fusion Pharma  (publicado em 23 de março de 2024).
• AstraZeneca has announced the acquisition of Amolyt Pharma  (publicado em 19 de março de 2024).
• Frontier Medicines acaba de anunciar uma arrecadação de fundos de 80 milhões de dólares. (publicado em 27 de fevereiro de 2024).

Outros contatos sugeridos na indústria do Farmacêutica

• Jean-Frédéric Paulsen - Executive Chairman of the Board da Ferring Pharmaceuticals
• Alice Schardt-Rossmann - Managing Director da Dirk Rossmann
• Thierry Abribat - Chief Executive Officer da Amolyt Pharma

Saiba mais sobre a indústria do Farmacêutica >

Últimos comunicados de imprensa de Everest Medicines

• Everest Medicines Announces Financial Results for Full Year Ended December 31, 2023 – Everest Medicines
• Everest Medicines Announces Financial Results for Full Year Ended December 31, 2023 – Everest Medicines
• Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer – Everest Medicines
• Everest Medicines Announces Singapore Health Sciences Authority Approves NEFEGAN® for the Treatment of Primary IgA Nephropathy in Adult Patients – Everest Medicines
• Everest Medicines’ Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon® – Everest Medicines
• Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer – Everest Medicines
• Everest Medicines Announces Singapore Health Sciences Authority Approves NEFEGAN® for the Treatment of Primary IgA Nephropathy in Adult Patients – Everest Medicines
• Everest Medicines’ Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon® – Everest Medicines
• Everest Medicines to Announce Full-Year 2023 Financial Results on March 28, 2024 – Everest Medicines
• Everest Medicines Announces Acceptance of VELSIPITY® New Drug Application in Macau – Everest Medicines
• View more press releases Close

Redes sociais sobre Everest Medicines

• Everest Medicines na Wikipedia, Google News e Yahoo Finance
• Everest Medicines na LinkedIn, Twitter e YouTube

Contate seus executivos por e-mail agora, incluindo Yifan Li

Ligue para a Everest Medicines em +1 203...

Veja o organograma

Register to receive your alert

Relatório um erro